A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Blood - 141(2023), 21 vom: 25. Mai, Seite 2654-2657 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Hao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69G8BD63PP |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 24.03.2024 published: Print ClinicalTrials.gov: NCT03982771 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2023020009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354337947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354337947 | ||
| 003 | DE-627 | ||
| 005 | 20240324234700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2023020009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM354337947 | ||
| 035 | |a (NLM)36928290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Hao |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03982771 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Zhang, Miao-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Kai-Ni |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xin-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Ming-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Dao-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 141(2023), 21 vom: 25. Mai, Seite 2654-2657 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:21 |g day:25 |g month:05 |g pages:2654-2657 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2023020009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2023 |e 21 |b 25 |c 05 |h 2654-2657 | ||